Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Cardiol J. 2012;19(6):567-77. doi: 10.5603/cj.2012.0107.
Arrhythmias play a significant role in the mortality and morbidity as well as hospitalizations of patients who carry a diagnosis of congestive heart failure. With improving survival in a world of novel medications and devices, an understanding of the pathophysiology and management of these arrhythmias is crucial. Majority of the basic heart failure medications such as beta- -blockers, angiotensin converting enzyme inhibitors/aldosterone receptor blockers and aldosterone antagonists play a pivotal role in prevention of sudden cardiac deaths which can be a direct/indirect result of these arrhythmias. Anti-arrhythmic drugs and implantable cardioverter-defibrillators were also beneficial in selected patients. Innovative electrophysiological techniques need to be considered in special situations.
心律失常在患有充血性心力衰竭诊断的患者的死亡率、发病率以及住院率中起着重要作用。随着新型药物和设备的出现,提高了患者的生存率,因此了解这些心律失常的病理生理学和治疗方法至关重要。大多数基本心力衰竭药物,如β-受体阻滞剂、血管紧张素转换酶抑制剂/醛固酮受体拮抗剂和醛固酮拮抗剂,在预防心律失常直接/间接导致的心脏性猝死方面发挥着关键作用。抗心律失常药物和植入式心脏复律除颤器也对某些患者有益。在特殊情况下,需要考虑创新的电生理技术。